东阿阿胶(000423) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 reached ¥1,718,524,479.25, representing an 18.24% increase compared to ¥1,453,383,433.75 in the same period last year[11] - Net profit attributable to shareholders was ¥424,976,597.42, up 20.25% from ¥353,403,544.67 year-on-year[11] - The net profit after deducting non-recurring gains and losses increased by 26.69%, amounting to ¥416,362,477.57 compared to ¥328,636,170.06 in the previous year[11] - Total revenue for the current period reached ¥1,718,524,479.25, an increase of 18.3% compared to ¥1,453,383,433.75 in the previous period[31] - Net profit for the current period was ¥425,021,406.21, representing a growth of 20.2% from ¥353,563,445.96 in the previous period[32] - Basic and diluted earnings per share increased to 0.6615 from 0.5488, reflecting a 20.5% rise[33] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥13,308,303,020.39, a 1.69% increase from ¥13,087,136,728.33 at the end of the previous year[11] - Total assets reached ¥13,308,303,020.39, compared to ¥13,087,136,728.33 in the previous period, indicating a growth of 1.7%[29] - Total liabilities decreased to ¥2,551,389,284.83 from ¥2,755,244,398.98, a reduction of 7.4%[29] - The total equity attributable to shareholders rose to ¥10,735,150,361.45 from ¥10,310,173,764.03, reflecting a growth of 4.1%[29] Cash Flow - The net cash flow from operating activities was negative at -¥304,127,676.76, a decline of 147.63% compared to a positive cash flow of ¥638,470,330.70 in the same period last year[11] - Operating cash flow for the current period is -304,127,676.76 yuan, a decrease from 638,470,330.70 yuan in the previous period, indicating a significant decline in operational performance[34] - Cash inflow from investment activities totaled ¥4,008,048,913.97, a 257.24% increase from ¥1,121,948,444.18 in the same period last year[17] - Cash inflow from investment activities increased to 4,008,048,913.97 yuan, compared to 1,121,948,444.18 yuan in the previous period, reflecting a strong investment recovery[35] - Total cash outflow from operating activities increased to 1,363,627,447.23 yuan, compared to 1,031,308,257.64 yuan in the previous period, indicating higher operational expenses[34] Shareholder Information - The total number of common shareholders at the end of the reporting period is 48,922[19] - The top 10 shareholders hold a combined 33.66% of the company's total share capital, with China Resources Dong'e Ejiao Co., Ltd. holding 23.50% and China Resources Pharmaceutical Investment Co., Ltd. holding 10.16%[20] - China Resources Pharmaceutical Investment Co., Ltd. has cumulatively increased its shareholding by 7,516,790 shares as of April 9, 2025[24] - The company has approved a stock incentive plan aimed at enhancing employee motivation and retention[22] Investment Performance - Investment income surged by 108.50%, reaching ¥19,748,920.32 compared to ¥9,471,782.54 in the previous year[16] - The company reported an investment income of ¥19,748,920.32, significantly higher than ¥9,471,782.54 in the previous period, showing improved investment performance[32] - The company reported a cash return from investments of 24,707,730.64 yuan, an increase from 11,938,020.63 yuan, indicating better investment performance[35] Other Financial Metrics - The weighted average return on equity improved to 4.04%, up from 3.25% in the previous year[11] - Research and development expenses were ¥38,728,875.37, slightly down from ¥39,199,038.29, indicating a focus on cost management[32] - The company's cash and cash equivalents increased to ¥5,431,608,203.79 from ¥5,014,911,161.46, reflecting a growth of approximately 8.3%[27] - The inventory balance at the end of the period was ¥962,303,141.77, slightly up from ¥926,249,627.14, showing a growth of about 3.9%[27] - Trading financial assets decreased to ¥2,803,255,333.75 from ¥3,519,212,876.21, a decline of approximately 20.3%[27] Related Party Transactions - The company has not disclosed any related party transactions among the top shareholders[20] - There are no preferred shareholders or related matters applicable for the reporting period[21] Audit Status - The company has not yet audited the first quarter report, which may affect the reliability of the financial data presented[36]